Chrysalis BioTherapeutics receives $3 million grant for nuclear countermeasure development
TP508 has significantly increased survival and delayed mortality when injected up to 24 hours after lethal radiation exposure in controlled preclinical studies. The award brings total NIAID funding to over $6M and allows Chrysalis to complete FDA approval studies.